Mesoblast

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Close Change

Score

-0.35

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 124 3.9 0.34% 0.49% 5.3% -2.4% 15.3%
SHORT 123 3.9 0.36% 0.53% 3.4% -2.3% -35.6%

Summary

Technical Analysis


The only price most market participants look at is the closing price in relation to the previous day’s close. As such the position of the close has the ability to highlight recent performance and indirectly the keenness of traders.

[Calculations] Close Today Versus Close Yesterday (CTCY):
1) [Close] > [Close Yesterday] = Buyers keener than sellers;
2) [Close] < [Close Yesterday] = Sellers keener than buyers;
3) [Close] = [Close Yesterday] = Neither are keener


PROFILE: Mesoblast (MSB.AX)


Stock Exchange: ASX
Company: Mesoblast
Ticker Codes: | MSB.AX | ASX:MSB |

About Mesoblast (ASX:MSB):

Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

Top 10:

Close Change

Download
Company Close Change(%) Volume Value Signal
EML Emerchants 4.35 13.6 7,106,370 1 BULLISH CROSSOVER
CGS Cogstate 0.36 12.5 54,332 1 BULLISH CROSSOVER
APX Appen 22.66 5.9 1,026,466 1 BULLISH CROSSOVER
NMT Neometals 0.2 5.3 241,577 1 BULLISH CROSSOVER
BAF Blue Sky Alternatives 0.92 5.1 936,302 1 BULLISH CROSSOVER
BSE BSE 0.22 4.9 77,053 1 BULLISH CROSSOVER
SGF SG Fleet 2.68 4.7 164,520 1 BULLISH CROSSOVER
BEE Broo 0.02 4.5 172,843 1 BULLISH CROSSOVER
SHM Shriro 0.72 4.3 7,177 1 BULLISH CROSSOVER
PSQ Pacific Smiles 1.77 4.1 3,500 1 BULLISH CROSSOVER